Hypoglycemic/ Anti-diabetic drug - Semaglutide & Metformin HCL
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Study Finds Semaglutide Lower Suicide Ideation Risk Compared to Other Diabetes and Obesity Medications
-
Are GLP-1 Receptor Agonists Linked to Hair Loss and Suicidal Thoughts?
-
Can New Entrants Succeed in the Competitive GLP-1 Drug Market?
-
'Weight loss needle' is coming to China soon! Why is Semaglutide the best GLP-1 student?
-
Semaglutide once a week for the treatment of adolescent obesity Phase III results appear in the New England Journal of Medicine: significantly reduce BMI
-
Semaglutide: Another phenomenon-level new drug, breaking one billion in 'seconds', and the 'weight loss' market is basically out of stock
-
The Global Pharmaceutical Innovation Index is released!
-
Semaglutide: The Dose Is Increased From 1mg To 2mg, The Efficacy Is Further Enhanced
-
GLP-1 competition: Semaglutide surpasses dulaglutide this year
-
Semaglutide initiates Phase III clinical trial of NASH in China
Recommend Reading
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Premium Global Chemical Sourcing Requests (26 - 29 Mar, 2026)
-
This Week's Maleic Anhydride Market Continues to Decline in China
-
Geopolitical Tensions Intensify, Causing a Significant Increase in Polyester Chip Prices
-
Weak Demand Leads to Decline in Toluene Market
-
Dow’s “Double Salvo”: Behind the €150/ton Hike, Europe’s Chemical Industry Is Being Strangled by a “Cost Noose”